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a b s t r a c t
The role of binding kinetics in determining neutralizing potency for antiviral antibodies is poorly understood.
While it is believed that increased steady-state afﬁnity correlates positively with increased virus-neutralizing
activity, the relationship between association or dissociation rate and neutralization potency is unclear. We
investigated the effect of naturally-occurring antibody resistance mutations in the RSV F protein on the
kinetics of binding to palivizumab. Escape from palivizumab-mediated neutralization of RSV occurred with
reduced association rate (Kon) for binding to RSV F protein, while alteration of dissociation rate (Koff) did not
signiﬁcantly affect neutralizing activity. Interestingly, linkage of reduced Kon with reduced potency mirrored
the effect of increased Kon found in a high-afﬁnity enhanced potency palivizumab variant (motavizumab).
These data suggest that association rate is the dominant factor driving neutralization potency for antibodies
to RSV F protein antigenic site A and determines the potency of antibody somatic variants or efﬁciency of
escape of viral glycoprotein variants.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Respiratory syncytial virus (RSV) is a single-stranded, negative-
sense RNA virus that is in the genus Pneumovirus of the family
Paramyxoviridae. RSV is a major pediatric pathogen that causes an
estimated 33 million cases of acute lower respiratory infections (ALRI)
in children worldwide per year (Nair et al., 2010). RSV is also a
signiﬁcant pathogen among elderly and immunocompromised popu-
lations (Falsey et al., 2005). The associated respiratory disease is
typically most serious during primary infection early in life, but
reinfection is common throughout life (Henderson et al., 1979). Certain
infants are at particular risk due to prematurity and underlying
cardiopulmonary disease, but prophylactic administration of the
high-afﬁnity RSV F-speciﬁc humanized murine monoclonal antibody
(mAb) palivizumab to at-risk pediatric populations is relatively
effective at preventing ALRI (Anon, 1998; Groothuis and Nishida.
2002; Top et al., 2000). Palivizumab is the only mAb for prevention
of viral disease licensed to date.
One of the concerns about wide-spread clinical use of a mAb to
prevent or treat infection with an RNA virus like RSV possessing an
error-prone RNA polymerase is that antibody-resistant mutant viruses
might emerge. Palivizumab-resistant viruses have been found in
circulation in the general population (Zhu et al., 2012). It is not clear
whether or not selection of antibody-resistant mutant viruses for
palivizumab occurs commonly in patients or not. Some resistant
strains have been observed in patients receiving palivizumab
(Zhu et al., 2011), although other similar studies did not detect
antibody-resistant viruses in patients on treatment (DeVincenzo
et al., 2004). Predictably, it is not difﬁcult to isolate palivizumab-
resistant viruses following growth of virus in cell culture in the
presence of antibody (Adams et al., 2010; Zhao et al., 2004, 2004;
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Zhu et al., 2011). Most palivizumab-resistant viruses, however, are
susceptible to an afﬁnity-matured version of palivizumab called
motavizumab (Zhu et al., 2011). Motavizumab was developed as a
somatic variant of palivizumab by synthetic means using engineered
point mutations in a palivizumab library and selection of expressed
high-afﬁnity variants based on optimized binding in vitro. Motavizu-
mab binds RSV F protein with an approximate 70-fold increase in
steady-state afﬁnity and exhibits a comparable increase in in vivo
efﬁcacy compared with the parental antibody palivizumab (Wu et al.,
2007). Interestingly, long periods of in vitro selection isolated variants
with long dissociation rates (Koff) (and thus improved steady-state KD)
but little functional improvement, while short time period selections
identiﬁed variants with improved association rates (Kon) that
mediated enhanced neutralizing potency (Wu et al., 2007). Other
studies to optimize palivizumab binding of RSV are consistent with
the association rate being the dominant factor in the ability of mAbs to
neutralize RSV by interacting with the RSV F protein antigenic site A
(Wu et al., 2005). We also have shown previously that a direct
relationship exists between association rate and RSV-neutralizing
activity of the human mAb Fab19 using germline reversion variations
of that antibody to remove individual somatic mutations in the
antibody that contribute to enhanced afﬁnity and potency (Bates
et al., 2013). Association rate is not necessarily the driving factor for all
antibody mediated viral neutralization, however, as studies with other
viral pathogens also have shown that virus inhibitory activity can be
determined predominantly by the dissociation rate (Kallewaard et al.,
2008; VanCott et al., 1994).
The above observations describe mechanisms of afﬁnity
maturation of neutralizing antibodies to the RSV F protein anti-
genic site A. Here, we investigated the opposite phenomenon –
escape from antibody-mediated neutralization by variation of the
viral glycoprotein sequence. We examined the effect of viral
resistance mutations in the RSV F protein on kinetics of antibody
binding to RSV F protein and neutralizing activity. We hypothe-
sized that RSV escape mutant viruses evade neutralization by
palivizumab principally by altering the association rate of antibody
binding, the mirror image of afﬁnity maturation of antibodies by
somatic mutations that optimize association rate.
Results
Effects of antigenic site A mutations on neutralizing activity
of palivizumab
Neutralization escape mutant viruses that possessed coding
changes in the antigenic site A region of the F protein were collected.
The effect of these mutations on the virus neutralizing activity of
palivizumab was determined by plaque reduction assay (Table 1). The
speciﬁc activity (concentration need to cause 60% reduction) of
palivizumab against wild-type RSV strain A2 was 0.57 mg/mL, which
is similar to previously published values (Wu et al., 2005). Palivizumab
activity for each of the monoclonal antibody resistant mutant (MARM)
viruses was reduced. K272N and S275F had the least effect, and
reduced the speciﬁc activity of palivizumab to 0.90 mg/mL. K272Q had
the greatest effect and reduced the neutralizing activity of palivizumab
to 408 mg/mL, a 716-fold reduction in activity.
Effects of antigenic site A mutations on binding of palivizumab to RSV
F proteins
We sought to determine the effect of RSV F mutations on
palivizumab binding experimentally. A number of mutations in RSV
F antigenic site A that confer resistance to palivizumab have been
identiﬁed previously by sequence analysis of the F gene escapemutant
viruses (Adams et al., 2010; Zhao et al., 2004; Zhu et al., 2011), and a
number of these mutations also reduce binding of palivizumab to RSV
F protein-expressing cells (Liu et al., 2007). We generated ten
recombinant variant RSV F protein molecules, each incorporating
one of the known palivizumab resistance mutations. Each of these
mutations falls within the antigenic site A of RSV F protein (Fig. 1). We
measured the association and dissociation rates and calculated steady-
state afﬁnity constants for palivizumab binding to each of the RSV F
protein variants (Table 2). The association rates varied from a 4.9-fold
decrease for K272Q to an insigniﬁcant increase of 1.2-fold for N268I
and S275F relative to wild-type RSV F protein. Dissociation rates were
increased for binding of palivizumab to each RSV F variant proteins.
N268I had no signiﬁcant effect, resulting in a 1.1-fold increase in
dissociation rate, while N262Y had the greatest effect and resulted in a
28-fold increase. The N262Y mutation had a much greater effect than
the S275F mutation, which resulted in a 4.2 fold increase in dissocia-
tion rate and had the second greatest effect.
Relationship of neutralizing activity to binding constants
To determine the relationship of changes in binding kinetics to
neutralization activity, we compared the values of Kon, Koff, or KD
Table 1
Palivizumab-selected monoclonal antibody resistant mutant viruses exhibit greater
antibody resistance in vitro.
MARMa Neutralizing activity (mg/ml) Fold reductionb








a Monoclonal antibody resistant mutant (MARM) viruses are labeled as the
wild-type amino acid followed by position and then the amino acid mutation
selected for by palivizumab-containing in vitro viral culture methods. All mutant
viruses derived from the RSV wild-type strain A2.
b Fold reduction was calculated by dividing the neutralizing activity against
each antibody escape mutant virus by the neutralizing activity against wild-type
RSV strain A2. A higher neutralizing activity, or larger fold reduction, denotes
greater viral resistance to antibody-mediated neutralization.
Antigenic
    site A
Fig. 1. The structure of RSV F and mutations that confer resistance to palivizumab.
(A) Antigenic Site A is shown in gold on the previously published structure of post-
fusion RSV F (PDBid: 3rrr). (B) The amino acid sequence of antigenic Site A is shown
in the context of the linearized, uncleaved RSV F. (C) Speciﬁc amino acid changes
within antigenic Site A which confer resistance to palivizumab are bolded and
underlined.
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for palivizumab binding to the variant RSV F proteins with the
corresponding neutralizing activity of palivizumab against each
respective virus (Fig. 2). Neutralizing activity correlated with Kon
(P¼0.02); faster association rate was associated with decreased
concentrated needed to neutralize. However, a signiﬁcant relation-
ship was not detected between neutralizing activity and Koff
(P¼0.32). The relationship between Kon and neutralizing activity
was strong enough that the KD of palivizumab binding to variant F
proteins also correlated signiﬁcantly with neutralizing activity
(P¼0.02).
Structural modeling of antigenic site A mutations at the RSV
F/palivizumab interface
Structural modeling was employed to explore possible struc-
tural explanations for the observed mutational effects on binding
kinetics. Based on the structure of the post-fusion RSV F protein
and the structure of a high-afﬁnity version of palivizumab (desig-
nated motavizumab) in complex with a site A peptide, we used the
ROSETTA molecular modeling platform to construct a plausible
structural model of the RSV F and palivizumab complex (see
Methods). Motavizumab has two phenylalanines in the HCDR3
(residues 98 and 100) at the interface that are part of a hydro-
phobic patch (McLellan et al., 2010), yet in the structural model of
palivizumab this patch is disrupted by a conformational and
sequence change in the HCDR3. The structural rearrangement
could be responsible for reduced binding afﬁnity of palivizumab
for RSV F. To gain a structural insight into the antibody escape
mutations, computer models were generated for each mutant. The
models were used to calculate the change in binding energy
mediated by the escape mutations. The ROSETTA binding energies
were reasonably correlated with experimental values (Table 3) and
the modeling correctly identiﬁed the escape mutation with the
largest experimentally measured Koff and the highest KD (N262Y;
see Table 2) as the most disruptive for steady-state binding. The
N262Y model suggests the bulky tyrosine side chain is bumping
into the light chain of palivizumab at W53 and that a mutation to a
smaller amino acid at residue 53 may resolve this clash.
Discussion
These studies revealed that potency of neutralization of varying
strains of RSV with the licensed neutralizing palivizumab corre-
lates directly with the association rate of the antibody binding to
antigenic site A. Interestingly, mutations in the RSV F protein
antigenic site A that altered the dissociation rate of this interaction
did not affect the neutralizing activity of palivizumab signiﬁcantly.
The results provide a snapshot of the dynamic interplay between
viruses and antibodies during which RNA viruses with variations
in neutralizing epitopes are selected if they do not signiﬁcantly
reduce ﬁtness for growth. The studies also give some speciﬁcity as
to the mechanism by which some mutations facilitate escape.
In this case, changes in the sequence of the viral protein that
reduced the Kon of binding by a neutralizing antibody promoted
the generation of antibody-resistant mutant viruses. These studies
of RSV F antibody resistance mutations are consistent with those
in previous studies of the palivizumab-F interaction showing that
alterations in the antibody protein sequence that enhance Kon, but
not changes that alter Koff, signiﬁcantly improve neutralizing
activity (Wu et al., 2005).
Table 2
Kinetics of binding of palivizumab to RSV F protein from wild-type or antibody-resistant mutant viruses.
RSV F proteina Kon (M1 s1) (104) Fold differenceb Koff (s1) (103) Fold differenceb KD (M) Fold differenceb
Wild-type 5.4 – 1.5 — 2.8108 —
N262Y 2.2 2.5 42.1 þ28 2.3106 79.6
N262S 4.0 1.4 2.8 þ1.9 8.3108 2.9
N268I 6.7 þ1.2 1.6 þ1.1 3.3108 1.1
K272E 1.7 3.2 3.5 þ2.3 2.1107 7.4
K272N 2.9 1.8 2.6 þ1.7 9.5108 3.3
K272Y 4.0 1.4 2.8 þ1.9 8.6108 3.0
K272M 1.7 3.2 4.3 þ2.9 2.5107 8.8
K272Q 1.1 4.9 3.0 þ2.0 2.6107 9.3
S275F 6.7 þ1.2 6.3 þ4.2 1.3107 4.5
N276Y 1.9 2.8 5.4 þ3.6 3.4107 11.8
a Designates the wild-type amino acid followed by position and then the palivizumab-selected escape amino acid.
b Fold differences were calculated by dividing the wild-type value by the selected mutant value for fold decreases () or dividing the selected antibody escape mutant
value by the wild-type giving fold increases (þ).
Fig. 2. Relationship between association rate (A), dissociation rate (B), and steady-state afﬁnity (C) of palivizumab binding to variant RSV F proteins with neutralizing activity
of palivizumab against viruses bearing the same mutations. The RSV F wild type sequence is shown in red. P values indicate Spearman's Rank Correlation.
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The correlation between neutralization and Kon observed here
likely reﬂects speciﬁc aspects of the biochemistry of infection by
RSV, but the mechanism underlying the structural effect is not
clear from current data. Any survival beneﬁt conferred by muta-
tions that reduce the Kon of antibody to RSV F must be balanced
against the resulting effect on the usual function of F protein in the
virus lifecycle. Several of the mutations studied here (K272N,
K272M, K272Q, and S275F) have been examined for their effect
on fusion activity of the RSV F protein (Liu et al., 2007). These
mutations confer resistance to palivizumab and simultaneously
enhance the fusogenic activity of RSV F (Liu et al., 2007). In the
case of K272M, the ﬁtness of the antibody resistant virus is
equivalent to that of wild-type RSV strain A2 (Zhao et al., 2006).
Sensitivity of virus to antibody binding with enhanced Kon is
consistent with a mechanism of virus neutralization in which
the virus is neutralized quickly and irreversibly. Recent reports
suggest that the structure of the antigenic site A epitope is not
transient but is preserved in the post-fusion form of RSV F, which
probably occurs after attachment to cells (McLellan et al., 2011).
Probably, the initial engagement of F with circulating antibodies is
the limiting step in RSV neutralization mediated by antibodies to
antigenic site A.
There are not enough instances of comparison of neutralization
potency with association or dissociation rates to know whether
Kon is the dominant component of binding energies driving
neutralization for most viruses and epitopes or not. Clearly, there
is some diversity in the factors that are needed for optimal virus
inhibition. For example, we have shown that inhibition of rotavirus
transcription by the human mAb RV6-26 offers a contrasting
nature of the effects of binding kinetics and potency of inhibition.
RV6-26 binds to a quaternary epitope of rotavirus VP6 protein in
the double-layered particle at the transcription pore and prevents
extrusion of RNA through the pore (Aiyegbo et al., 2013). In this
antibody/virus combination, mutations that increase Koff result in
signiﬁcantly lower speciﬁc inhibitory activity (Kallewaard et al.,
2008), thus the Koff appears to be the component of the KD that
best correlates with neutralizing activity. Because RNA extrusion
likely occurs over a relatively long time compared to RSV viral
fusion, the ability of the antibody to remain bound to rotavirus
likely is more important than the rate at which it binds, reﬂecting
a mechanism of inhibition in which optimized Koff may be of
particular beneﬁt.
There are other instances in which KD alone does not fully
inform the mechanisms underlying the biology of neutralization.
Steckbeck et al. have shown that mutations in SIV gp120 that alter
Kon and Koff but not the KD can confer resistance to neutralization
(Steckbeck et al., 2005). Consequently, it is conceivable that two
different antibodies could bind the same epitope with the same
steady-state afﬁnity but differences in Kon and Koff could determine
signiﬁcantly different proﬁles of neutralizing activity.
Such subtle differences in antibody-antigen binding interac-
tions in the context of infection will be an important consideration
in future structure-based vaccine development and in the




RSV variant strains that were selected to be resistant to murine
mAbs or palivizumab by growth and selection of escape mutant
strains in the presence of antibody were described previously
(Beeler and van Wyke Coelingh, 1989). We previously determined
the sequences of the F protein genes for the resistant mutants,
identifying critical point mutations (Crowe et al., 1998). These
virus strains were isolated from the wild-type strain RSV A2.
Suspensions of the antibody resistant or wild-type strains were
prepared by collecting clariﬁed supernates from HEp-2 cell mono-
layer cultures inoculated at 0.1 m.o.i.. Suspensions were stored at
80 1C until use in the assays.
Measurement of palivizumab-mediated neutralizing activity against
wt or antibody-resistant RSV
The neutralizing activity of palivizumab directed towards
antibody-sensitive wt virus or a panel of antibody-resistant viruses
was measured by a plaque reduction assay using HEp-2 monolayer
cell culture. The activity was measured in mg/mL and calculated as
the lowest concentration of palivizumab IgG needed to reduce
plaque number by 60%. Diluted wt RSV strain A2 or previously
characterized palivizumab-resistant RSV mutant viruses were
suspended to yield 50 plaques per well and were mixed with
1:4 dilutions of palivizumab IgG, and incubated at 37 1C for
60 min. Cell monolayers in 24-well tissue culture plates at 80%
conﬂuency were inoculated in duplicate by replacing the medium
in each well with 100 ml of virus-antibody mixture. After incuba-
tion at 37 1C for 1 h, cell monolayers then were overlaid with 0.75%
methylcellulose in Opti-MEM I (Invitrogen) supplemented with 2%
FBS, 320 mg/mL l-glutamine, 2.7 mg/mL amphotericin B, and 45 mg/
mL gentamicin. Cultures were incubated for 5 days at 37 1C in 5%
CO2 after which the overlay was removed and the monolayers
were ﬁxed in 80% cold methanol. Plaques were stained and
quantiﬁed by an immunoperoxidase staining procedure as
described previously (Murphy et al., 1990). Plaques for each anti-
body concentration were counted, triplicate values averaged, and
antibody concentration versus plaque number plotted. The 60%
plaque reduction neutralizing activity (mg/mL) was determined by
regression curve analysis.
Computational methods
The interactions of wt and mutant RSV F proteins with
palivizumab were modeled using the ROSETTA simulation plat-
form (Leaver-Fay et al., 2011). The complex of palivizumab and RSV
F has not yet been crystallized. To make a model of the palivizu-
mab/RSV F complex, a homology model was constructed based on
the crystal structure (PDBid: 3ixt) of the motavizumab antibody in
complex with a peptide corresponding to the motavizumab/
palivizumab epitope on RSV F (McLellan et al., 2010). First, we
expanded the motavizumab crystal structure to include the full
RSV F protein by structurally aligning and then replacing the
Table 3
Comparison of experimental dG to computational binding energies.




WT 10.3 45 27
N262Y 7.7 273 236
N262S 9.7 47 27
N268I 10.2 111 91
K272E 9.1 48 30
K272N 9.6 46 27
K272Y 9.6 61 29
K272M 9 49 28
K272Q 9 47 28
S275F 9.4 74 44
N276Y 8.8 54 28
R¼0.63 R¼0.62
R values show the correlation coefﬁcient between the experimental dG and
computationally determined dE for each computational method.
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peptide from 3ixt with the RSV F post-fusion trimer structure
(PDBid: 3rrr) (McLellan et al., 2011). Second, we built a model of
palivizumab by modeling the amino acids from the palivizumab
sequence onto the motavizumab crystal structure. However, the
structure alignment of the unbound palivizumab crystal structure
(2hwz) onto motavizumab highlighted a difference in the HCDR3
conformations. Thus, the motavizumab HCDR3 was replaced by
the palivizumab HCDR3 in the homology model, and a ﬂexible
backbone modeling protocol in ROSETTA was used to alleviate
clashes to the HCDR3. The ﬁnal palivizumab/RSV F was subjected
to a constrained relax procedure. Each RSV F mutant was created
using the standard ﬁxed-backbone and side-chain minimization
procedure. All the models were scored as a complex and unbound
components, and then the binding score was computed with the
standard ROSETTA score12 score function.
Construction of recombinant soluble ectodomain RSV F protein
expression vectors
The wild-type (wt) RSV F ectodomain construct (pcDNA3.1-
FECTO-myc/His), was constructed by PCR ampliﬁcation of the
ectodomain, removing the transmembrane domain and cytoplas-
mic tail regions from full-length RSV Fopt cDNA (domains and
construct previously described) (Brock et al., 2005). The PCR
product was cloned directionally into pcDNA3.1/myc-His B (Invi-
trogen) using restriction sites 5´-BamHI-EcoRI-30. Ligated product
was transformed into E. coli strain DH5α competent cells, and
plasmids were puriﬁed with the QIAprep Miniprep Kit (Qiagen).
Antibody-resistant forms of RSV F protein were generated by
introducing known amino acid changes from the F gene sequence
of palivizumab-resistant viruses (see Fig. 1) into our F construct
using QuikChange Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA), per the manufacturer's protocol. All plasmid constructs
were sequenced to conﬁrm in-frame cloning with the C-terminal
c-myc epitope and polyhistidine (6xHis) tag of the expression
vector.
Protein expression and puriﬁcation of wt or escape mutant RSV
F recombinant protein
The pcDNA3.1-FECTO-myc/His plasmids (wt or escape mutant
forms) were transfected into 293-F suspension cells as recom-
mended by the manufacturer (Freestyle 293 Expression System,
Invitrogen). Transfected cells were incubated for 4 days, then the
cells were centrifuged for 10 min at 100 g at 4 1C and super-
natant ﬁltered through 0.2 μm ﬁlters prior to puriﬁcation and
stored at 4 1C. Puriﬁcation of 6xHis-tagged RSV FECTO protein
was performed by immobilized metal ion afﬁnity chromato-
graphy using pre-packed 5 mL HisTrap HP Ni-Sepharose columns
(GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to
the manufacturer's recommended protocol. Puriﬁed protein was
concentrated and dialyzed against PBS through Amicon Ultra
centrifugal ﬁlters with a 30 kilodalton molecular weight cutoff
(Millipore, Billerica, MA). Puriﬁed preparations were identiﬁed by
denaturing, non-reducing SDS-PAGE analysis as a single, silver-
stained band with the expected 60 kilodalton migration. Concen-
tration was determined by Bradford dye assay. Puriﬁed protein
was stored at 4 1C until analyzed.
Measurement of kinetics of palivizumab IgG binding to RSV F proteins
The association and dissociation rates of wt or escape mutant
RSV F recombinant protein with palivizumab IgG were measured
on a Biacore 2000 biosensor (Biacore AB, Uppsala, Sweden).
Palivizumab IgG (Synagis; MedImmune, Gaithersburg, MD, USA)
was diluted to 30 mg/mL in 10 mM sodium acetate, pH 4.5, and
covalently immobilized at 5 ml/min by amine coupling to the
dextran matrix of a CM5 sensor chip (Biacore AB, Uppsala,
Sweden). Unreacted, active ester groups on the sensor chip were
blocked with 1 M ethanolamine. For use as a reference, a blank
surface, containing no palivizumab, was prepared under identical
immobilization conditions. Each puriﬁed wt or antibody escape
mutant RSV F protein was prepared at 5 different concentrations
ranging from 5 to 500 nM in HBS/Tween-20 buffer (Biacore AB,
Uppsala, Sweden), and injected over the immobilized palivizumab
IgG and reference cell surfaces. Each RSV F protein, at every
concentration, was run in triplicate. RSV F protein binding was
measured at a ﬂow rate of 30 mL/min for 180 s and dissociation
was monitored for an additional 360 s. Residual bound RSV F
protein after each cycle was removed from the sensor chip by
ﬂowing 50 mM HCl at 100 mL/min for 30 s. Association rates (Kon)
and dissociation rates (Koff) were calculated by aligning the
binding curves globally to ﬁt a 2:1 binding model using BIAeva-
luation 4.1 software (Biacore AB, Uppsala, Sweden). Calculated
rates were accepted only if the goodness of each ﬁt based on the
agreement between experimental data and the calculated ﬁts had
a χ2 value below 5. The afﬁnity values then were calculated for the
interaction of trimeric F protein with palivizumab IgG on the chip
from the equation
kof f =kon ¼ KD:
We chose to use the 2:1 binding model after preliminary
evaluation of the ﬁt of binding curve using several models
incorporating varying ratios of interaction revealed that the 2:1
binding model exhibited the best χ2 values for interaction of
trimeric F with bivalent IgG.
Statistics
Spearman's rank correlation was used to determine if changes
in antibody binding kinetics among the RSV F variants had a
signiﬁcant impact on RSV neutralizing activity.
Acknowledgments
We thank Scott A. Smith, Natalie J. Thornburg, and Jessica Finn
for helpful discussions. JEC was supported by a Clinical Scientist
Award in Translational Research from the Burroughs Wellcome
Fund. CJK was supported by an award from the Pediatric Scientist
Development Program, which receives grants from the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development (NICHD) (K12HD000850) and numerous private
agencies and foundations.
References
Adams, O., Bonzel, L., Kovacevic, A., Mayatepek, E., Hoehn, T., Vogel, M., 2010.
Palivizumab-resistant human respiratory syncytial virus infection in infancy.
Clin Infect Dis 51, 185–188.
Aiyegbo, M.S., Sapparapu, G., Spiller, B.W., Eli, I.M., Williams, D.R., Kim, R., Lee, D.E.,
Liu, T., Li, S., Woods , V.L., Nannemann, D.P., Meiler, J., Stewart, P.L., Crowe , J.E.,
2013. Human rotavirus VP6-speciﬁc antibodies mediate intracellular neutrali-
zation by binding to a quaternary structure in the transcriptional pore. PLoS
One 8, e61101.
Anon, 1998. Palivizumab, a humanized respiratory syncytial virus monoclonal
antibody, reduces hospitalization from respiratory syncytial virus infection in
high-risk infants. The IMpact-RSV Study Group. Pediatrics 102:531–537.
Bates, J.T., Keefer, C.J., Utley, T.J., Correia, B.E., Schief, W.R., Crowe , J.E., 2013.
Reversion of Somatic Mutations of the Respiratory Syncytial Virus-Speciﬁc
Human Monoclonal Antibody Fab19 Reveal a Direct Relationship between
Association Rate and Neutralizing Potency. J Immunol 190, 3732–3739.
Beeler, J.A., van Wyke Coelingh, K., 1989. Neutralization epitopes of the F
glycoprotein of respiratory syncytial virus: effect of mutation upon fusion
function. J Virol 63, 2941–2950.
J.T. Bates et al. / Virology 454-455 (2014) 139–144 143
Brock, S.C., Heck, J.M., McGraw, P.A., Crowe , J.E., 2005. The transmembrane domain
of the respiratory syncytial virus F protein is an orientation-independent apical
plasma membrane sorting sequence. J Virol 79, 12528–12535.
Crowe, J.E., Firestone, C.Y., Crim, R., Beeler, J.A., Coelingh, K.L., Barbas, C.F., Burton, D.
R., Chanock, R.M., Murphy, B.R., 1998. Monoclonal antibody-resistant mutants
selected with a respiratory syncytial virus-neutralizing human antibody fab
fragment (Fab 19) deﬁne a unique epitope on the fusion (F) glycoprotein.
Virology 252, 373–375.
DeVincenzo, J.P., Hall, C.B., Kimberlin, D.W., Sanchez, P.J., Rodriguez, W.J., Jantausch,
B.A., Corey, L., Kahn, J.S., Englund, J.A., Suzich, J.A., Palmer-Hill, F.J., Branco, L.,
Johnson, S., Patel, N.K., Piazza, F.M., 2004. Surveillance of clinical isolates of
respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect
Dis 190, 975–978.
Falsey, A.R., Hennessey, P.A., Formica, M.A., Cox, C., Walsh, E.E., 2005. Respiratory
syncytial virus infection in elderly and high-risk adults. N Engl J Med 352,
1749–1759.
Groothuis, J.R., Nishida, H., 2002. Prevention of respiratory syncytial virus infections
in high-risk infants by monoclonal antibody (palivizumab). Pediatr Int 44,
235–241.
Henderson, F.W., Collier, A.M., Clyde , W.A., Denny, F.W., 1979. Respiratory-
syncytial-virus infections, reinfections and immunity. A prospective, long-
itudinal study in young children. N Engl J Med 300, 530–534.
Kallewaard, N.L., McKinney, B.A., Gu, Y., Chen, A., Prasad, B.V., Crowe , J.E., 2008.
Functional maturation of the human antibody response to rotavirus. J Immunol
180, 3980–3989.
Leaver-Fay, A., Tyka, M., Lewis, S.M., Lange, O.F., Thompson, J., Jacak, R., Kaufman, K.,
Renfrew, P.D., Smith, C.A., Shefﬂer, W., Davis, I.W., Cooper, S., Treuille, A.,
Mandell, D.J., Richter, F., Ban, Y.E., Fleishman, S.J., Corn, J.E., Kim, D.E., Lyskov, S.,
Berrondo, M., Mentzer, S., Popovic, Z., Havranek, J.J., Karanicolas, J., Das, R.,
Meiler, J., Kortemme, T., Gray, J.J., Kuhlman, B., Baker, D., Bradley, P., 2011.
ROSETTA3: an object-oriented software suite for the simulation and design of
macromolecules. Methods Enzymol 487, 545–574.
Liu, C., Day, N.D., Branigan, P.J., Gutshall, L.L., Sarisky, R.T., Del Vecchio, A.M., 2007.
Relationship between the loss of neutralizing antibody binding and fusion
activity of the F protein of human respiratory syncytial virus. Virol J 4, 71.
McLellan, J.S., Chen, M., Kim, A., Yang, Y., Graham, B.S., Kwong, P.D., 2010. Structural
basis of respiratory syncytial virus neutralization by motavizumab. Nat Struct
Mol Biol 17, 248–250.
McLellan, J.S., Yang, Y., Graham, B.S., Kwong, P.D., 2011. Structure of respiratory
syncytial virus fusion glycoprotein in the postfusion conformation reveals
preservation of neutralizing epitopes. J Virol 85, 7788–7796.
Murphy, B.R., Sotnikov, A.V., Lawrence, L.A., Banks, S.M., Prince, G.A., 1990.
Enhanced pulmonary histopathology is observed in cotton rats immunized
with formalin-inactivated respiratory syncytial virus (RSV) or puriﬁed F
glycoprotein and challenged with RSV 3-6 months after immunization. Vaccine
8, 497–502.
Nair, H., Nokes, D.J., Gessner, B.D., Dherani, M., Madhi, S.A., Singleton, R.J., O'Brien,
K.L., Roca, A., Wright, P.F., Bruce, N., Chandran, A., Theodoratou, E., Sutanto, A.,
Sedyaningsih, E.R., Ngama, M., Munywoki, P.K., Kartasasmita, C., Simoes, E.A.,
Rudan, I., Weber, M.W., Campbell, H., 2010. Global burden of acute lower
respiratory infections due to respiratory syncytial virus in young children: a
systematic review and meta-analysis. Lancet 375, 1545–1555.
Steckbeck, J.D., Orlov, I., Chow, A., Grieser, H., Miller, K., Bruno, J., Robinson, J.E.,
Montelaro, R.C., Cole, K.S., 2005. Kinetic rates of antibody binding correlate
with neutralization sensitivity of variant simian immunodeﬁciency virus
strains. J Virol 79, 12311–12320.
Top , F.H., Connor, E.M., Carlin, D.A., 2000. Prophylaxis against respiratory syncytial
virus in premature infants. IMpact-RSV Study Group. Lancet 355, 1014.
VanCott, T.C., Bethke, F.R., Polonis, V.R., Gorny, M.K., Zolla-Pazner, S., Redﬁeld, R.R.,
Birx, D.L., 1994. Dissociation rate of antibody-gp120 binding interactions is
predictive of V3-mediated neutralization of HIV-1. J Immunol 153, 449–459.
Wu, H., Pfarr, D.S., Tang, Y., An, L.L., Patel, N.K., Watkins, J.D., Huse, W.D., Kiener, P.A.,
Young, J.F., 2005. Ultra-potent antibodies against respiratory syncytial virus:
effects of binding kinetics and binding valence on viral neutralization. J Mol Biol
350, 126–144.
Wu, H., Pfarr, D.S., Johnson, S., Brewah, Y.A., Woods, R.M., Patel, N.K., White, W.I.,
Young, J.F., Kiener, P.A., 2007. Development of motavizumab, an ultra-potent
antibody for the prevention of respiratory syncytial virus infection in the upper
and lower respiratory tract. J Mol Biol 368, 652–665.
Zhao, X., Chen, F.P., Megaw, A.G., Sullender, W.M., 2004. Variable resistance to
palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis
190, 1941–1946.
Zhao, X., Chen, F.P., Sullender, W.M., 2004. Respiratory syncytial virus escape
mutant derived in vitro resists palivizumab prophylaxis in cotton rats. Virology
318, 608–612.
Zhao, X., Liu, E., Chen, F.P., Sullender, W.M., 2006. In vitro and in vivo ﬁtness of
respiratory syncytial virus monoclonal antibody escape mutants. J Virol 80,
11651–11657.
Zhu, Q., McAuliffe, J.M., Patel, N.K., Palmer-Hill, F.J., Yang, C.F., Liang, B., Su, L., Zhu,
W., Wachter, L., Wilson, S., MacGill, R.S., Krishnan, S., McCarthy, M.P., Losonsky,
G.A., Suzich, J.A., 2011. Analysis of respiratory syncytial virus preclinical and
clinical variants resistant to neutralization by monoclonal antibodies palivizu-
mab and/or motavizumab. J Infect Dis 203, 674–682.
Zhu, Q., Patel, N.K., McAuliffe, J.M., Zhu, W., Wachter, L., McCarthy, M.P., Suzich, J.A.,
2012. Natural polymorphisms and resistance-associated mutations in the
fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility
to palivizumab. J Infect Dis 205, 635–638.
J.T. Bates et al. / Virology 454-455 (2014) 139–144144
